NCT02238756View on ClinicalTrials.gov

Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

November 30, 2016

Conditions
Rabies
Interventions
BIOLOGICAL

CV8102

Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart

BIOLOGICAL

Rabipur

Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart

BIOLOGICAL

CV8102 + Rabipur

Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart

Trial Locations (1)

Unknown

CRS Clinical Research Services Mönchengladbach GmbH, Mönchengladbach

Sponsors

Lead Sponsor

CureVac
All Listed Sponsors
lead

CureVac

INDUSTRY

NCT02238756 - Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter